JP Morgan Chase
ENFN

JP Morgan Chase’s Enfusion, Inc. ENFN Stock Holding History

JP Morgan Chase’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-126,693
Closed -$1.41M – 7851
2025
Q1 		$1.41M Sell
126,693
-176,639
-58% -$1.95M ﹤0.01% 4111
2024
Q4 		$3.12M Buy
303,332
+95,310
+46% +$921K ﹤0.01% 3804
2024
Q3 		$1.97M Buy
208,022
+178,821
+612% +$1.54M ﹤0.01% 4020
2024
Q2 		$249K Buy
29,201
+10,827
+59% +$99.1K ﹤0.01% 5045
2024
Q1 		$170K Sell
18,374
-6,594
-26% -$58K ﹤0.01% 5430
2023
Q4 		$242K Sell
24,968
-739
-3% -$6.9K ﹤0.01% 5276
2023
Q3 		$231K Sell
25,707
-19,917
-44% -$189K ﹤0.01% 4980
2023
Q2 		$512K Sell
45,624
-310,285
-87% -$2.75M ﹤0.01% 4479
2023
Q1 		$3.74M Buy
355,909
+333,982
+1,523% +$3.68M ﹤0.01% 3042
2022
Q4 		$212K Buy
21,927
+2,867
+15% +$32.3K ﹤0.01% 5004
2022
Q3 		$235K Sell
19,060
-1,820
-9% -$22.2K ﹤0.01% 4876
2022
Q2 		$213K Buy
20,880
+5,310
+34% +$58.7K ﹤0.01% 5053
2022
Q1 		$198K Sell
15,570
-101
-0.6% -$1.54K ﹤0.01% 5203
2021
Q4 		$328K Buy
+15,671
New +$317K ﹤0.01% 5077

Other funds holding ENFN

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's ENFN Position: Q2 2025 in Review

JP Morgan Chase sold out of Enfusion, Inc. (ENFN) in Q2 2025, closing a stake of 126,693 shares — an estimated $1.41M sold.

JP Morgan Chase first reported a position in ENFN in Q4 2021 and held it in 14 quarters. The position peaked at $3.74M in Q1 2023. 2 funds tracked by Wall St. Rank hold ENFN as of Q2 2025.

  • JP Morgan Chase reported no remaining Enfusion, Inc. position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 126,693 Enfusion, Inc. shares in Q2 2025, an estimated $1.41M.
  • JP Morgan Chase first reported a position in Enfusion, Inc. in Q4 2021 and held it in 14 quarters.
  • JP Morgan Chase's Enfusion, Inc. position peaked at $3.74M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.